M/F | 36/3 | 1/5** | 3/1 | 40/9 | 5/10 |
Mean (SE) age (years) | 60.4 (1.7) | 48.7 (4.7)* | 49.2 (5.7) | 58.0 (1.6) | 34.1 (2.1) |
Smoking status | | | | | |
Current | 6 (15%) | 1 (17%) | 1 (25%) | 8 (16%) | 1 (7%) |
Ex | 25 (64%) | 2 (33%) | 3 (75%) | 30 (61%) | 2 (13%) |
Never | 8 (21%) | 3 (50%) | 0 | 11 (22%) | 12 (80%) |
Lung biopsy | 8 (21%) | 5 (83%) | 2 (50%) | 15 (31%) | |
No treatment | 22 | 4 | 0 | 26 | |
Prednisolone alone | 7 | 1 | 1 | 9 | |
Prednisolone+azathioprine | 4 | 0 | 2 | 6 | |
Other combination | 6 | 1 | 1 | 8 | |
Mean (range) duration of symptoms (months) | 52.5 (1.5–192) | 26.3 (4–109) | 29.8 (3–90) | 45.9 (1.5–192) | |
Mean (SE) lung function (% predicted) |
FEV1 | 71.6 (3.1) | 65.7 (9.3) | 64.1 (3.8) | 69.8 (2.7) | |
FVC | 67.6 (3.1) | 62.9 (9.7) | 60.8 (6.3) | 66.0 (2.8) | |
TLC | 65.1 (2.7) | 73.1 (19.4) | 64.7 (6.7) | 64.6 (2.5) | |
Tlco | 40.8 (2.2) | 42.0 (24.1) | 44.2 (7.8) | 41.1 (2.0) | |
Plasma IL-8 (pg/ml) | 194 (86–307) | 172 (36–296) | 101 (42–357) | 155 (77–303) | 31 (0.0–100) |
Plasma VEGF (pg/ml) | 662 (449–918) | 739 (401–862) | 878 (652–2014) | 672 (452–915) | 648 (433–734) |
Plasma ET-1 (pg/ml) | 1.21 (0.88–2.00) | 1.22 (0.80–1.66) | 1.18 (0.94–2.33) | 1.21 (0.91–1.88) | 0.84 (0.67–1.13) |